ATHE - Alterity Therapeutics Appoints Phillip Hains as Chief Financial Officer | Benzinga
MELBOURNE, Australia and SAN FRANCISCO, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the appointment of Phillip Hains as the Company's new Chief Financial Officer (CFO), effective 31 January 2024.
Mr. Hains has served as the Company Secretary of Alterity since 2014, and his experience includes almost 30 years in corporate secretarial, accounting and general management through professional services firm Acclime and predecessor firm The CFO Solution.
The appointment of Mr. Hains follows the resignation of Kathryn Andrews, who has been CFO since 2014. Ms. Andrews has chosen to leave Alterity to pursue other interests and will continue to support the Company during the transition.
David Stamler, M.D., Chief Executive Officer of Alterity, commented, "On behalf of the Board of Directors and management team, we would like to express our deep appreciation to Kathryn for her valuable contributions to the Company during her tenure as CFO, and we wish her well for the future. We look forward to expanding our relationship with Phillip as we enter 2024 which will be a pivotal year for us."
About Alterity Therapeutics Limited
Alterity Therapeutics is ...